Sponsor or institution
Clinical trials and research at Sinotau Pharmaceutical Group
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Sinotau Pharmaceutical Group that are recruiting, in China. By phase: Phase 3 (2), Phase 2/3 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| PET imaging with XTR003 and 18F-FDG to find recoverable heart muscle in ischemic cardiomyopathy | Phase 2 | Beijing, Beijing Municipality and 2 other locations | Recruiting | Mar 2, 2026 |
| XTR004 PET heart scan to detect flow‑limiting coronary blockages | Phase 3 | Beijing and 4 other locations | Recruiting | Feb 27, 2026 |
| 18F‑XTR006 PET imaging to detect brain tau (neurofibrillary tangles) in normal, MCI, and Alzheimer’s patients | Phase 3 | Beijing, Beijing Municipality | Recruiting | Aug 11, 2025 |
| Lutetium-177 Lu-oxodotreotide for Advanced Neuroendocrine Neoplasms | Phase 2/3 | Shanghai, Shanghai Municipality | Recruiting | May 3, 2024 |
All recruiting trials (4)
-
PET imaging with XTR003 and 18F-FDG to find recoverable heart muscle in ischemic cardiomyopathy
This trial tests whether adding XTR003 injection to 18F‑FDG PET scans helps identify living heart muscle in adults (18–85) with ischemic cardiomyopathy who are candidates for complete revascularization.
-
XTR004 PET heart scan to detect flow‑limiting coronary blockages
This trial tests whether XTR004 PET heart scans can accurately detect significant coronary artery blockages in adults with suspected or known coronary artery disease compared with QCA and FFR.
-
18F‑XTR006 PET imaging to detect brain tau (neurofibrillary tangles) in normal, MCI, and Alzheimer’s patients
We will test whether an injected PET tracer called XTR006 can detect neurofibrillary tangles in people aged 50 and older who are cognitively normal, have mild cognitive impairment, or have Alzheimer’s disease.
-
Lutetium-177 Lu-oxodotreotide for Advanced Neuroendocrine Neoplasms
This study tests Lutetium-177Lu oxodotreotide in people with inoperable or advanced neuroendocrine tumors to see how safe it is and whether it helps shrink tumors.
Quick answers
How many clinical trials run by Sinotau Pharmaceutical Group are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2/3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.